A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

ClinicalTrials.gov ID: NCT03305016

Public ClinicalTrials.gov record NCT03305016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Study identification

NCT ID: NCT03305016
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Enrollment: 146 participants

Conditions and interventions

Conditions

Interventions

TransCon hGH Drug

Drug

Eligibility (public fields only)

Age range: 6 Months to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 12, 2017
Primary completion: Mar 18, 2019
Completion: Mar 18, 2019
Last update posted: Jul 6, 2026

2017 – 2019

United States locations

U.S. sites: 21
U.S. states: 14
U.S. cities: 20

Facility	City	State	ZIP	Site status
University of Alabama	Birmingham	Alabama	35233	—
Neufeld Medical Group Inc.	Los Angeles	California	90048	—
Center of Excellence in Diabetes and Endocrinology	Sacramento	California	95821	—
Rocky Mountain Pediatric Endocrinology	Centennial	Colorado	80112	—
Nemours Children's Health System	Jacksonville	Florida	32207	—
Orlando Health Inc.	Orlando	Florida	32806	—
Tallahassee Memorial Hospital	Tallahassee	Florida	32308	—
University of Iowa	Iowa City	Iowa	52242	—
Children's Minnesota	Saint Paul	Minnesota	55102	—
University of Mississippi Medical Center	Jackson	Mississippi	39216	—
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
NYU Winthrop Hospital	Mineola	New York	11501	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma	73104	—
Children's Diabetes and Endocrine Center	Portland	Oregon	97227	—
Oregon Health & Science University	Portland	Oregon	97239	—
Children's Medical Center	Dallas	Texas	75235	—
Cook Children's Medical Center	Fort Worth	Texas	76104	—
University of Virginia Children's Hospital	Charlottesville	Virginia	22903	—
Children's Hospital of The King's Daughters	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03305016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 6, 2026 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03305016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →